229 related articles for article (PubMed ID: 29317233)
21. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases.
Hoch BL; Nielsen GP; Liebsch NJ; Rosenberg AE
Am J Surg Pathol; 2006 Jul; 30(7):811-8. PubMed ID: 16819322
[TBL] [Abstract][Full Text] [Related]
22. SNF5 as a prognostic factor in skull base chordoma.
Li M; Zhai Y; Bai J; Wang S; Gao H; Li C; Gui S; Du J; Zhang Y
J Neurooncol; 2018 Mar; 137(1):139-146. PubMed ID: 29222701
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report.
Ares C; Hug EB; Lomax AJ; Bolsi A; Timmermann B; Rutz HP; Schuller JC; Pedroni E; Goitein G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1111-8. PubMed ID: 19386442
[TBL] [Abstract][Full Text] [Related]
24. Impact of cytogenetic abnormalities on the management of skull base chordomas.
Almefty KK; Pravdenkova S; Sawyer J; Al-Mefty O
J Neurosurg; 2009 Apr; 110(4):715-24. PubMed ID: 19133754
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas.
Lin E; Scognamiglio T; Zhao Y; Schwartz TH; Phillips CD
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1509-1514. PubMed ID: 29903925
[TBL] [Abstract][Full Text] [Related]
26. Chordomas: Histopathological Study in View of Anatomical Location.
Cha YJ; Suh YL
J Korean Med Sci; 2019 Apr; 34(13):e107. PubMed ID: 30950252
[TBL] [Abstract][Full Text] [Related]
27. Whole-transcriptome analysis of chordoma of the skull base.
Bell D; Raza SM; Bell AH; Fuller GN; DeMonte F
Virchows Arch; 2016 Oct; 469(4):439-49. PubMed ID: 27401718
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological implications of TIM3
Zhou J; Jiang Y; Zhang H; Chen L; Luo P; Li L; Zhao J; Lv F; Zou D; Zhang Y; Jing Z
Cancer Immunol Immunother; 2019 Jul; 68(7):1157-1169. PubMed ID: 31197461
[TBL] [Abstract][Full Text] [Related]
29. Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.
Wang L; Tian K; Ma J; Wang K; Jia G; Wu Z; Zhang L; Zhang J
Acta Neurochir (Wien); 2017 Oct; 159(10):1803-1813. PubMed ID: 28699066
[TBL] [Abstract][Full Text] [Related]
30. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.
Horbinski C; Oakley GJ; Cieply K; Mantha GS; Nikiforova MN; Dacic S; Seethala RR
Arch Pathol Lab Med; 2010 Aug; 134(8):1170-6. PubMed ID: 20670138
[TBL] [Abstract][Full Text] [Related]
32. Skull base chordomas: clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors.
Boari N; Gagliardi F; Cavalli A; Gemma M; Ferrari L; Riva P; Mortini P
J Neurosurg; 2016 Aug; 125(2):450-60. PubMed ID: 26745472
[TBL] [Abstract][Full Text] [Related]
33. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability.
Naka T; Boltze C; Samii A; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Cancer; 2003 Nov; 98(9):1934-41. PubMed ID: 14584077
[TBL] [Abstract][Full Text] [Related]
34. Genomic and transcriptomic characterization of skull base chordoma.
Sa JK; Lee IH; Hong SD; Kong DS; Nam DH
Oncotarget; 2017 Jan; 8(1):1321-1328. PubMed ID: 27901492
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.
Zou MX; Lv GH; Zhang QS; Wang SF; Li J; Wang XB
World Neurosurg; 2018 Jan; 109():307-327. PubMed ID: 29045855
[TBL] [Abstract][Full Text] [Related]
36. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
37. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
38. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.
Longoni M; Orzan F; Stroppi M; Boari N; Mortini P; Riva P
Neuro Oncol; 2008 Feb; 10(1):52-60. PubMed ID: 18094369
[TBL] [Abstract][Full Text] [Related]
40. Photon-based fractionated stereotactic radiotherapy for postoperative treatment of skull base chordomas.
Bugoci DM; Girvigian MR; Chen JC; Miller MM; Rahimian J
Am J Clin Oncol; 2013 Aug; 36(4):404-10. PubMed ID: 22772429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
